Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance^®) in Type 2 diabetic patients inadequately controlled on metformin

Abstract

Intensive management of Type 2 DM with a new metformin-glibenclamide combination tablet improved glycaemic control and facilitated the attainment of glycaemic targets at lower doses of metformin or glibenclamide compared with the respective monotherapies, without compromising tolerability.